The pharmaceutical and health-care supply chain is characterised by unprecedented levels of change. The UK pharmaceutical wholesaling component is no exception, especially in view of its traditional position as a middleman. Over the past five years, structural changes to both business models and operating practices employed by upstream manufacturers have had fundamental repercussions for industry wholesalers. Read the fill report on IBIS.